



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

BSE Ltd.
P. J. Towers
Dalal Street
Mumbai 400 001

February 4, 2020

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Presentation

Enclosed is investor presentation on consolidated performance during quarter ended on December 31, 2019.

Kindly take the same on record.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. Chemicals & Pharmaceuticals Limited

EARNINGS PRESENTATION | Q3 -FY20



Disclaimer

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management JB Chemicals & Pharmaceuticals Limited ("Company" or "JBCPL" or "JB Chemicals & Pharmaceuticals Limited"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



For further information please contact our Investor Relations Representatives:

Mr. Anuj Sonpal

Valorem Advisors



Tel: +91-22-4903-9500

Email: jbcp1@valoremadvisors.com



Company Overview

- J.B Chemicals and Pharmaceuticals Ltd. (JBCPL) was incorporated in 1976 under the chairmanship of Mr. J.B Mody.
- Over the past four decades JBCPL has established brands not only in India but also internationally to 30+ countries, supplying affordable and quality products.
- JBCPL's product portfolio is spread across chronic and acute therapeutic segments like cardio vascular, gastro, anti-microbials, NSAID, etc.
- The company manufactures a wide range of innovative specialty products across dosage forms like tablets, injectable, creams & ointments, lozenges, herbal liquids and capsules.
- The company has 8 manufacturing facilities across Gujarat and Daman, with USFDA approved Tablet plant and API plants.
- The R & D facilities are DSIR approved located in Maharashtra, Gujarat and Daman.




Performance Highlights

Consolidated




Sales



Q3 FY 19 Q3 FY 20

YTD Dec 19 YTD Dec 20


EBITDA



Q3 FY 19 Q3 FY 20

YTD Dec 19 YTD Dec 20

PAT



Q3 FY 19 Q3 FY 20

YTD Dec 19 YTD Dec 20



Q3-2019-20 Consolidated Financial Performance

(Rs. in crores)

Particulars	Q3			YTD December, 2019		
	2019-20	2018-19	YoY Growth (%)	2019-20	2018-19	YoY Growth (%)
Sales	420.04	372.86	14.16	1303.66	1198.22	16.04
Other Operating income	8.59	9.17	(6.32)	27.50	26.06	5.53
Other Income	16.38	15.82	3.54	47.50	25.79	84.18
Total Income	445.01	397.85	11.85	1378.66	1250.07	10.29
Operating Profit (EBIT)	72.85	63.32	15.05	236.90	196.26	20.71
EBITDA	89.60	77.98	14.90	285.84	240.30	18.95
Profit before tax	88.37	77.84	13.53	281.87	218.71	28.88
Profit after tax	66.44	49.9	33.15	222.32	147.18	51.05
EPS (Rs.) (FV 2)	15.99	6.07		27.66	17.86	



Q3-2019-20 Consolidated Sales Performance

(Rs. in crores)

Sales	Q3			YTD December, 2019		
	2019-20	2018-19	YoY Growth (%)	2019-20	2018-19	YoY Growth (%)
Domestic Formulations	183.97	161.15	14.16	595.00	512.73	16.04
Formulations exports	139.76	133.07	5.02	449.39	442.76	1.50
API Business	17.78	19.49	(8.77)	56.56	58.13	(2.70)
Subsidiary Sales	71.57	54.92	30.32	184.50	169.98	8.54
Other Sales	6.96	4.23	64.53	18.21	14.62	24.56
Total Sales	420.04	372.86	12.65	1303.66	1198.22	8.80

Performance Highlights



(Rs. in crores)

	Sales Q3 2019-20	Sales Q3 2018-19	Growth (%)
Domestic Formulations	168.66	148.29	13.74
Domestic Contrast Media	15.30	12.85	19.07
Russia-CIS	39.26	38.08	3.10
Global Business (RoW)	156.07	138.37	12.79
Other formulations exports	16.00	11.53	38.76
API Sales	17.78	19.49	(8.77)

Performance Highlights



- EBIDTA of Rs. 89.60 crores was 21.33% of sales, up from 20.91% in the same quarter in previous year, due to cost optimization.
- Sales of Russian subsidiary (included in Russia-CIS above) was Rs. 26.55 crores, increase of 48% over the same quarter previous year.
- Sales of South African subsidiary (included in Global business above) was Rs. 45 crores, increase of 21.8% over the same quarter previous year.
- Company completed buy-back of 29,54,545 shares. The paid-up equity share capital now stand at 7,72,82,097 equity shares of Rs. 2 each.

Quarterly - Consolidated Income Statement

(Rs. in Lakhs)



PARTICULARS	Actual 2019-20	% to Sales	Actual 2018-19	% to Sales	Growth %
Net Sales	42,004.2	100.0	37,285.7	100.0	12.7%
Operating Income	859.1	2.0	916.9	2.5	-6.3%
Total Income	42,863.3	102.0	38,202.6	102.5	12.2%
Cost Of Materials	15,034.8	35.8	12,638.9	33.9	19.0%
Gross Profit	27,828.5	66.3	25,563.8	68.6	8.9%
Employees Benefits Expenses	8,231.6	19.6	7,225.9	19.4	13.9%
Other Expenses	10,861.9	25.9	10,526.0	28.2	3.2%
Exch. Fluc. (Gain) / Loss	(224.7)	(0.5)	14.2	0.0	1685.7%
EBITDA (Operating)	8,959.6	21.3	7,797.7	20.9	14.9%
Finance Costs	85.3	0.2	129.7	0.3	-34.2%
Depreciation	1,674.9	4.0	1,466.0	3.9	14.2%
Profit Before Tax (Operating)	7,199.4	17.1	6,202.0	16.6	16.1%
Other Income	1,638.0	3.9	1,582.0	4.2	3.5%
Profit Before Tax	8,837.4	21.0	7,784.1	20.9	13.5%
Prov -taxation (Net)	2,192.7	5.2	2,788.9	7.5	-21.4%
Profit After Taxation	6,644.7	15.8	4,995.1	13.4	33.0%
Other Comprehensive Income	696.4	1.7	(631.5)	(1.7)	-210.3%
Total Comprehensive Income After Tax	7,341.1	17.5	4,363.6	11.7	68.2%



YTD - Consolidated Income Statement

(Rs. in Lakhs)

PARTICULARS	Actual 2019-20	% to Sales	Actual 2018-19	% to Sales	Growth %
Net Sales	1,30,366.3	100.0	1,19,822.6	100.0	8.8%
Operating Income	2,749.7	2.1	2,605.9	2.2	5.5%
Total Income	1,33,116.0	102.1	1,22,428.5	102.2	8.7%
Cost Of Materials	48,380.2	37.1	43,248.8	36.1	11.9%
Gross Profit	84,735.8	65.0	79,179.7	66.1	7.0%
Employees Benefits Expenses	23,739.2	18.2	21,347.4	17.8	11.2%
Other Expenses	32,511.6	24.9	33,163.9	27.7	-2.0%
Exch. Fluc. (Gain) / Loss	(98.6)	(0.1)	638.1	0.5	115.5%
EBITDA (Operating)	28,583.7	21.9	24,030.2	20.1	18.9%
Finance Costs	253.1	0.2	334.0	0.3	-24.2%
Depreciation	4,893.3	3.8	4,404.2	3.7	11.1%
Profit Before Tax (Operating)	23,437.3	18.0	19,292.0	16.1	21.5%
Other Income	4,749.6	3.6	2,578.9	2.2	84.2%
Profit Before Tax	28,186.9	21.6	21,870.9	18.3	28.9%
Prov -taxation (Net)	5,954.8	4.6	7,153.0	6.0	-16.8%
Profit After Taxation	22,232.1	17.1	14,717.9	12.3	51.1%
Other Comprehensive Income	315.8	0.2	(695.8)	(0.6)	-145.4%
Total Comprehensive Income After Tax	22,547.9	17.3	14,022.1	11.7	60.8%